The table below shows Immunome Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$58.64M
-$53.05M
-$11.17M
$24.17M
-$6.38M
-$3.54M
Capital expenditure
$3.00M
$3.67M
$2.16M
$106.00K
$6.00K
$31.00K
Investing cash flow
-$12.02M
$5.09M
-$37.23M
-$106.00K
-$6.00K
-$31.00K
Dividends paid
-
-
-
-
IMNM operating cash flow (10-K history)
Immunome Inc. reported operating cash flow of -$190.92M for fiscal year 2025. That is down 72.3% from -$110.79M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$9.60M (FY 2019) to -$190.92M. Figures come from the company's audited annual reports as filed with the SEC.